Health
Monoclonal antibodies against MERS coronavirus show promise in phase 1 trial – Medical Xpress
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory…
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe when administered simultaneously to healthy adults. The experimental mAbs, REGN3048 and REGN3051, target the MERS coronavirus (MERS CoV) spike protein used by the virus to attach to and infect target cells. The mAbs were discovered and developed by scientists at the biopharmaceutical…
-
General23 hours agoDonald Trump’s initial 10 per cent tariff takes effect
-
General22 hours agoJaguar Land Rover in UK pauses shipments to US
-
General20 hours agoTexas opens probe into Kellogg’s health claims, dyes
-
General18 hours agoAustralian share market set to dive as threat of US recession grows